Novo Nordisk(US:NVO) Prnewswireยท2025-09-24 14:05Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Novo Nordisk A/S due to allegations of misleading statements regarding the company's growth potential and market capabilities, particularly related to its GLP-1 products [3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Novo between May 7, 2025, and July 28, 2025, to contact them for discussing legal options [1]. - A federal securities class action has been filed against Novo, with a deadline of September 30, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against Novo - The complaint alleges that Novo and its executives violated federal securities laws by making false or misleading statements and failing to disclose the true state of the company's growth potential [3]. - Specific claims include that Novo's potential to capitalize on the compounded market was greatly understated, and the likelihood of patients switching to Novo's branded alternatives was overstated [3]. Group 3: Stock Performance Impact - Following Novo's announcement of lowered sales and profit outlook on July 29, 2025, the company's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [4].